Smith & Nephew gets in on Michelson Diagnostics Series B round
February 16, 2015 by Brad Perriello
Smith & Nephew put down the cornerstone in the 1st tranche of Michelson Diagnostics’ $3.8 million (£2.5 million) Series B round for its skin cancer detection device.
Kent, U.K.-based Michelson’s VivoSight device uses optical coherence tomography to generate images of tissues and vasculature beneath the skin. Smith & Nephew contributed $2.3 million (£1.5 million) to the Series B tranche, which also included new investor the Kent County Council, and existing backers. Read more
Diabetes: Valeritas registers $90m IPO
February 13, 2015 by Brad Perriello
Valeritas yesterday registered for an initial public offering worth up to $90 million for its V-Go insulin delivery system.
Bridgewater, N.J.-based Valeritas said it plans to list on the NASDAQ exchange under the “VLRX” symbol. Read more
HeartFlow raises $36m for non-invasive FFR system
February 13, 2015 by Mark Hollmer
HeartFlow said it raised more than $35.8 million, 2 months after gaining FDA clearance for its non-invasive fractional flow reserve test to diagnose and treat coronary artery disease.
The Redwood City, Calif.-based company is seeking to raise a total of $46.3 million from the equity round, according to a regulatory filing. Read more
Bellerophon prices $60m IPO low, issues more shares
February 13, 2015 by Brad Perriello
Bellerophon Therapeutics priced its initial public offering under range today but offered more shares than planned, for total proceeds of $60 million.
Hampton, N.J.-based Bellerophon had planned to raise up to $69 million by putting up 4 million shares at $14 to $16, but wound up floating 5 million shares at $12 apiece. Read more
Rainbow Medical raises $25m for China ops
February 17, 2015 by Brad Perriello
Rainbow Medical said yesterday that it pulled down $25 million from a syndicate of Chinese investors for a new operation in the People’s Republic, aimed at promoting “strategic collaborations” there.
“We opened the office in Shanghai to capitalize on China’s fast-growing market for our products and to foster collaborations with Chinese medical device companies,” co-founder & CEO Efi Cohen-Arazi said in prepared remarks. “These investments by leading Chinese industrial and financial entities are an expression of the high esteem with which they view our technologies and the products we are developing. There is a strong demand in the fast-growing Chinese healthcare industry for Rainbow Medical’s breakthrough technologies.” Read more
